A LinkedIn post from Actithera indicates that the company plans to attend the American Association for Cancer Research Annual Meeting in 2026. The post notes that Head of Oncology and Translational Science Jacques Moisan, PhD, will participate in the event and engage with researchers, partners, and innovators.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The content suggests Actithera is actively positioning itself within the oncology and radioligand therapy research community. For investors, visible participation at AACR may signal an emphasis on scientific networking, potential partnering, and staying aligned with emerging trends in cancer research, which could be relevant to future collaboration or pipeline development prospects.